Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9870
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasticity; and neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc (ACOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Venture Financing 15
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Private Equity 19
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Equity Offering 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Debt Offering 29
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Asset Transactions 33
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Acquisition 34
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc – Key Competitors 40
Acorda Therapeutics Inc – Key Employees 41
Acorda Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Strategy And Business Planning 44
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44
Financial Announcements 45
Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45
Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47
May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48
Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50
Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60
Corporate Communications 62
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62
Product News 63
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63
Clinical Trials 64
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc, Key Competitors 40
Acorda Therapeutics Inc, Key Employees 41
Acorda Therapeutics Inc, Subsidiaries 42

List of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oil Refineries Ltd (ORL):企業の財務・戦略的SWOT分析
    Oil Refineries Ltd (ORL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Inovio Pharmaceuticals Inc (INO)-医療機器分野:企業M&A・提携分析
    Summary Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing a portfolio of DNA vaccines (immunotherapies) for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology a …
  • Shanghai Electric Power Co Ltd (600021):企業の財務・戦略的SWOT分析
    Summary Shanghai Electric Power Co., Ltd. (Shanghai Electric Power), a subsidiary of State Power Investment Corporation is an electric energy company that generates and supplies electricity and thermal power. The company generates electricity from coal-fired plants, gas-fired plants, IGCC, gas power …
  • Zhejiang Jianfeng Group Company Ltd (600668):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Jianfeng Group Company Ltd (Jianfeng) is a diversified company. The company operates in the business of manufacturing cement, pharmaceuticals, health products, telecommunication and cables. It offers cement products that includes composite, ordinary, and slag Portland cement product …
  • KUKA AG (KU2):企業の財務・戦略的SWOT分析
    KUKA AG (KU2) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • DNO ASA (DNO):企業の財務・戦略的SWOT分析
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It also provides operations in petroleum, shipp …
  • NV Nederlandse Spoorwegen:企業の戦略・SWOT・財務情報
    NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report Summary NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • CyberOptics Corp (CYBE):企業の財務・戦略的SWOT分析
    Summary CyberOptics Corp (CyberOptics) is a technology company that offers high precision 3D sensors. The company’s products include SMT inspection, semiconductor and MRS sensors. CyberOptics SMT inspection provides solder paste inspection systems, automated optical inspection systems, and software …
  • Nagasaki University:製薬・医療:M&Aディール及び事業提携情報
    Summary Nagasaki University is an educational service provider that operates graduate schools, undergraduate schools, and research institutes. The university offers under graduate level education in the fields of economics, dentistry, pharmaceutical sciences, medicine, environmental studies, enginee …
  • Monsanto Company (MON)-製薬・医療分野:企業M&A・提携分析
    Summary Monsanto Company (Monsanto) is an agricultural products manufacturing company. It develops and delivers agricultural products to support farmers all around the world. The company develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other …
  • TriLink BioTechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TriLink BioTechnologies Inc (TriLink), a subsidiary of Maravai Life Sciences Inc, is a manufacturer of modified nucleic acid products. The company’s products include oligonucleotides, nucleotides, custom chemistry, DNA synthesis reagents, cleanamp PCR products, modified nucleoside triphospha …
  • Hitachi Zosen Corporation:戦略・SWOT・企業財務分析
    Hitachi Zosen Corporation - Strategy, SWOT and Corporate Finance Report Summary Hitachi Zosen Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Newfield Exploration Company:企業のM&A・事業提携・投資動向
    Newfield Exploration Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Newfield Exploration Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Aohata Corporation:企業の戦略・SWOT・財務分析
    Aohata Corporation - Strategy, SWOT and Corporate Finance Report Summary Aohata Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Basic Energy Services Inc (BAS):石油・ガス:M&Aディール及び事業提携情報
    Summary Basic Energy Services Inc (Basic Energy) is an oil and gas company that offers well site services. The company’s services including well servicing, snubbing, water logistics, saltwater disposal, pumping services, coil tubing, water solutions, wireline, contract drilling, coil tubing and tubu …
  • Coal India Ltd:企業のM&A・事業提携・投資動向
    Coal India Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Coal India Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Karolinska Institute-医療機器分野:企業M&A・提携分析
    Summary Karolinska Institutet (KI) is a medical university that offers education services. The university provides education and research in the fields of medicine and health sciences. Its education courses include audiology, biomedicine, biomedical lab science, dental hygiene, medicine, nursing, oc …
  • MCC EuroChem:企業の戦略的SWOT分析
    MCC EuroChem - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Samsung Engineering Co Ltd (028050):企業の財務・戦略的SWOT分析
    Samsung Engineering Co Ltd (028050) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Datatec Ltd (DTC):企業の財務・戦略的SWOT分析
    Datatec Ltd (DTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆